Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/10/2005WO2005105771A1 Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
11/10/2005WO2005105769A2 Mycophenolate mofetil impurity
11/10/2005WO2005105766A2 Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them
11/10/2005WO2005105765A1 Nitric oxide donors and uses thereof
11/10/2005WO2005105763A1 Substituted morpholine compounds for the treatment of central nervous system disorders
11/10/2005WO2005105758A1 Tri-substituted ureas as cytokine inhibitors
11/10/2005WO2005105757A1 Tri-substituted ureas as cytokine inhibitors
11/10/2005WO2005105754A1 Pyrazole phenyl derivatives as ppar activators
11/10/2005WO2005105751A1 Processes for preparing montelukast sodium
11/10/2005WO2005105744A1 Histamine-3 receptor antagonists
11/10/2005WO2005105743A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof
11/10/2005WO2005105739A2 Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
11/10/2005WO2005105733A1 Ortho substituted aryl or heteroaryl amide compounds
11/10/2005WO2005105732A1 Substituted methyl aryl or heteroaryl amide compounds
11/10/2005WO2005105731A1 Novel crystalline calcium pantothenate
11/10/2005WO2005105722A1 Crystal comprising (2r)-2-propyloctoic acid and amine
11/10/2005WO2005105712A1 Sulfonamide derivatives
11/10/2005WO2005105214A1 Compositions comprising water-insoluble fullerenes and their use for preventing damages caused by free radicals
11/10/2005WO2005105213A2 Indole and azaindole derivatives with antitumor action
11/10/2005WO2005105170A1 Bone substitute compositions and method of use
11/10/2005WO2005105159A2 Contrast agents for myocardial perfusion imaging
11/10/2005WO2005105147A2 Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases
11/10/2005WO2005105145A1 Treatment of infectious diseases
11/10/2005WO2005105128A1 Methods of producing treated ganoderma lucidum product and processed ganoderma lucidum product
11/10/2005WO2005105125A1 Preventive or remedy for osteroporosis
11/10/2005WO2005105123A1 Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency
11/10/2005WO2005105119A1 5-aminosalicylic acid of slow-released type in magnetic intercalated structure and the preparation method thereof
11/10/2005WO2005105116A2 Inhibition of biogenic sulfide production via biocide and metabolic inhibitor combination
11/10/2005WO2005105115A1 Functionalised siloxanes for scar tissue treatment
11/10/2005WO2005105114A1 Administration of enoxaparin sodium to patients 75 years and older with st-segment elevation myocardial infarction
11/10/2005WO2005105113A2 Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine
11/10/2005WO2005105112A2 Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions
11/10/2005WO2005105111A1 Artificial lung surfactant composition and method of using the same
11/10/2005WO2005105110A2 Doxepin analogs and methods of use thereof
11/10/2005WO2005105109A1 Oral modified-release lozenges and their preparation method
11/10/2005WO2005105108A1 The use of timosaponin bii in preparing the drug or produce of preventing and treating stroke
11/10/2005WO2005105107A2 Hormone treatment of multiple sclerosis
11/10/2005WO2005105106A2 Hormone treatment of macular degeneration
11/10/2005WO2005105105A2 Kit for treating hot flashes
11/10/2005WO2005105104A1 Transdermal steroid formulation
11/10/2005WO2005105103A2 Management of breakthrough bleeding in extended hormonal contraceptive regimens
11/10/2005WO2005105102A1 Improved nsaid composition
11/10/2005WO2005105101A1 Use of meloxicam formulations in veterinary medicine
11/10/2005WO2005105100A1 Morpholine compounds
11/10/2005WO2005105099A1 Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
11/10/2005WO2005105098A2 Preparation for the treatment of cancer
11/10/2005WO2005105097A2 Pyridopyrimidines for treating inflammatory and other diseases
11/10/2005WO2005105096A2 Fused heterocyclic compounds
11/10/2005WO2005105095A1 The combination for treating hyperlipemia
11/10/2005WO2005105094A2 Cancer treatment method
11/10/2005WO2005105093A2 METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
11/10/2005WO2005105092A2 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity
11/10/2005WO2005105091A1 Fluorinated 4-azasteroids as androgen receptor modulators
11/10/2005WO2005105090A1 Compositions for progeny gender control
11/10/2005WO2005105089A1 Remedy for psychoneurotic diseases
11/10/2005WO2005105088A2 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
11/10/2005WO2005105087A2 Methods of diminishing co-abuse potential
11/10/2005WO2005105086A1 Method for reducing gastrointestinal toxicity due to the administration of tegafur
11/10/2005WO2005105085A1 Compositions and methods for treatment of acne
11/10/2005WO2005105084A1 Alternative forms of the phosphodiesterase-4 inhibitor n-cyclopropyl-1-{3-[(1-oxidopryidin-3-yl)ethynyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide
11/10/2005WO2005105083A1 Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
11/10/2005WO2005105082A1 Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
11/10/2005WO2005105081A2 Therapeutic formulations of desoxyepothilones
11/10/2005WO2005105080A1 Combination therapy to treat diarrhea induced by cancer treatment
11/10/2005WO2005105079A2 Novel imidazoles
11/10/2005WO2005105078A1 Indole derivatives useful for treating resistance to antitumour agents
11/10/2005WO2005105077A1 Inflammatory eye disease
11/10/2005WO2005105075A1 Tri-substitued 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
11/10/2005WO2005105074A2 Composition for treating or preventing cell degeneration using at least one molecule capable of maintaining adhesion molecule expression reversibility and vascular endothelium actin fibre polymerisation
11/10/2005WO2005105073A1 Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
11/10/2005WO2005105072A2 Antifungal drug delivery
11/10/2005WO2005105071A1 A topical composition containing a vitamin d derivative
11/10/2005WO2005105070A2 Therapeutic antimicrobial compositions and methods
11/10/2005WO2005105069A1 Statins for the treatment of ocular hypertension and glaucoma
11/10/2005WO2005105068A1 In vivo stimulation of intestinal transporters for excretion of nitrogenous wastes
11/10/2005WO2005105067A2 Aqueous solutions comprising prednisolone and a cyclodextrin derivative
11/10/2005WO2005105066A2 Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases
11/10/2005WO2005105065A2 Thiazole-based nitric oxide donors for treating inflammatory bowel diseases
11/10/2005WO2005105064A2 Modulators of frat-lrp interaction in the treatment of bone-related diseases
11/10/2005WO2005105063A1 Pharmaceutical compositions containing serms for the treatment of alzheimer's disease
11/10/2005WO2005105062A2 2-methylthiazolidine-2,4-dicarboxylic acid-containing combination preparations
11/10/2005WO2005105061A2 Transdermal patch
11/10/2005WO2005105059A1 Permeation enhancer comprising genus curcuma or germacrone for transdermal and topical administration of active agents
11/10/2005WO2005105055A1 Formulation comprising histone deacetylase inhibitors
11/10/2005WO2005105052A1 Novel oral formulations of ospemifene
11/10/2005WO2005105049A2 Orally disintegrating tablets and methods of manufacture
11/10/2005WO2005105046A1 Controlled release drug delivery systems and methods for treatment of an eye
11/10/2005WO2005105045A1 Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
11/10/2005WO2005105044A1 Process for making inclusion complex of sulfonylureas having improved aqueous solubility
11/10/2005WO2005105043A2 Pharmaceutical compositions
11/10/2005WO2005105042A1 Buccal, polar and non-polar sprays containing propofol
11/10/2005WO2005105040A2 Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
11/10/2005WO2005105039A1 Solid pharmaceutical form comprising an ltb4 antagonist
11/10/2005WO2005105036A1 Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
11/10/2005WO2005105025A1 Methods and compositions for preventing or treating periodontal diseases
11/10/2005WO2005105009A1 Wound treatment patch for alleviating pain
11/10/2005WO2005104841A1 Micronized organic preservative formulations
11/10/2005WO2005104696A2 Non-gmo metal amino acid chelates and non-gmo metal amino acid chelate-containing compositions
11/10/2005WO2005095326A3 2-amino- and 2-thio-substituted 1,3-diaminopropanes
11/10/2005WO2005089503A3 Cd4-igg2 formulations
1 ... 4471 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 ... 7860